Tubeimoside I Inhibits the Proliferation of Liver Cancer Through Inactivating NF-κB Pathway by Regulating TNFAIP3 Expression
Our study provides compelling evidence that TBMS1 suppresses liver cancer progression by inactivating the NF-κB pathway and regulating TNFAIP3 expression. These findings offer novel insights and a theoretical basis for the development of targeted therapies for liver cancer.
Authors
- Liwen Zhu
- Langxuan Chen (ORCID: https://orcid.org/0000-0003-4196-9697)
- Zhen Huang (ORCID: https://orcid.org/0009-0008-3557-6903)
- Mingqin Zhou
- Hongzhong Zhou
- Haohua Zhang
- Yajun Zhang (ORCID: https://orcid.org/0009-0002-2437-7227)
Institutions
- Guangzhou University of Chinese Medicine (CN)
- Southern University of Science and Technology (CN)
- Shantou University (CN)
- Cancer Hospital of Shantou University Medical College (CN)
- Shenzhen Maternity and Child Healthcare Hospital (CN)
- Shenzhen Second People's Hospital (CN)
- Shenzhen Third People’s Hospital (CN)
Publication Details
- Journal
- Drug Design Development and Therapy
- Published
- 2025-03-01
- DOI
- https://doi.org/10.2147/dddt.s507656
- Citations
- 4
- Primary Topic
- Natural product bioactivities and synthesis
- Type
- article
- Field-Weighted Citation Impact
- 3.22